Table 1 Characteristics of 229 patients treated with EBRT-BT and EBRT alone for prostate cancer
Characteristics | Total | Group A EBRT-BT | Group B EBRT | p (Mann–Whitney U test) |
|---|---|---|---|---|
(N =229) | (N =99) | (N =130) | ||
Age [years] | 0.046 | |||
Median | 66 | 65 | 67 | |
Range | 49-83 | 49-83 | 51-80 | |
Zubrod score | 0.1 | |||
0 | 196 (85.6%) | 89 (89.9%) | 107 (82.3%) | |
1 | 32 (14%) | 10 (10.1%) | 22 (16.9%) | |
2 | 1 (0.4%) | 0 (0%) | 1 (0.8%) | |
PSA [ng/ml] | 0.463 | |||
Mean | 16.3 | 15.4 | 16.9 | |
Median | 12.3 | 11.8 | 13.9 | |
Range | 1.7-64 | 3.9-56.6 | 1.7-64 | |
PSA[ng/ml] | 0.962 | |||
<10 | 81 (35.4%) | 33 (33.3%) | 48 (36.9%) | |
10-20 | 91 (39.7%) | 44 (44.4%) | 47 (36.2%) | |
>20 | 57 (24.9%) | 22 (22.2%) | 35 (26.9%) | |
Gleason score | 0.122 | |||
2-6 | 115 (67.7%) | 67 (67.7%) | 88 (67.7%) | |
7 | 39 (17%) | 18 (18.2%) | 21 (16.2%) | |
8-10 | 22 (9.6%) | 8 (8.1%) | 14 (10.8%) | |
unknown | 13 (5.6%) | 6 (6%) | 7 (5.3%) | |
Clinical T stage | 0.118 | |||
T1b | 8 (3.5%) | 2 (2%) | 6 (4.6%) | |
T1c | 95 (41.7%) | 39 (39.4%) | 56 (43.1%) | |
T2a | 49 (21.3%) | 19 (19.2%) | 30 (23.1%) | |
T2b | 26 (11.3%) | 12 (12.1%) | 14 (10.7%) | |
T2c | 51 (22.2%) | 27 (27.3%) | 24 (18.5%) | |
Risk group | 0.310 | |||
LR | 48 (21%) | 18 (18.2%) | 30 (23.1%) | |
IR | 82 (35.8%) | 35 (35.3%) | 47 (36.1%) | |
HR | 99 (43.2%) | 46 (46.5%) | 53 (40.8%) | |
ADT | ||||
Neoadjuvant | 206 (90%) | 88 (89.8%) | 118 (90.7%) | 0.639 |
Adjuvant | 97 (42.4%) | 32 (32.3%) | 65 (50%) | 0.008 |
Salvage | 63 (27.4%) | 37 (37.4%) | 26 (20%) | 0.004 |
no | 11 (4.8%) | 4 (4%) | 7 (5.3%) | |
Total duration of ADT [months] | <0.001 | |||
Median | 98.9 | 6 | 13 | |
Range | 0.5-79 | 0.7-55.6 | 0.5-79 | |
Whole pelvis EBRT | 84 (36.7%) | 40 (40.4%) | 44 (33.9%) | 0.309 |
PSA nadir [ng/ml] | 0.049 | |||
Median | 0.04 | 0.07 | 0.03 | |
Range | 0-12.3 | 0-12.3 | 0-3.1 | |
Time to obtain PSA nadir [months] | 0.007 | |||
Median | 6.3 | 5.3 | 8.7 | |
Range | 0.9-74.9 | 1.1-58.4 | 0.9-74.9 |